Clinical Trials Logo

Rejection Acute Pancreas clinical trials

View clinical trials related to Rejection Acute Pancreas.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04166149 Active, not recruiting - Clinical trials for Transplant;Failure,Kidney

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

PancDX
Start date: September 1, 2019
Phase:
Study type: Observational

Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of interstitial fibrosis (IF) and tubular atrophy (TA) seen in biopsy specimens. Here, we will study the utility of dd-cfDNA to predict rejection in pancreas and pancreas-kidney recipients.